Zhitong Finance App News, Kangchen Pharmaceutical (603590.SH) announced that recently, KC1086 tablets (“KC1086” for short) independently developed by the company successfully completed the first case of the “KC1086 combined with fluorovisgroup for HR+/HER2- Locally Advanced or Metastatic Breast Cancer Phase II Clinical Study (KC1086-COM-01)”.

Zhitongcaijing · 2d ago
Zhitong Finance App News, Kangchen Pharmaceutical (603590.SH) announced that recently, KC1086 tablets (“KC1086” for short) independently developed by the company successfully completed the first case of the “KC1086 combined with fluorovisgroup for HR+/HER2- Locally Advanced or Metastatic Breast Cancer Phase II Clinical Study (KC1086-COM-01)”.